Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 5 of 5 entries
View as:

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

Phase: N/A Priority: Normal
NCT ID: NCT02558348 Org: User:
Start: 11/30/15 End: 05/30/17 Due: 05/30/18

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05612191 Org: User:
Start: - End: - Due: -

A Study of AL8326 in Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06794957 Org: User:
Start: 05/19/22 End: 12/31/27 Due: 12/31/28

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Phase: N/A Priority: Normal
NCT ID: NCT02584478 Org: User:
Start: 12/31/15 End: 12/31/24 Due: 12/31/25

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Phase: N/A Priority: Normal
NCT ID: NCT03016819 Org: User:
Start: 08/15/17 End: 06/30/25 Due: 06/30/26